Comparative Pharmacology
Head-to-head clinical analysis: AVIANE 21 versus AVLAYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVIANE 21 versus AVLAYAH.
AVIANE-21 vs AVLAYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; inhibits gonadotropin secretion, suppressing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
AVLAYAH is a combination of ethinyl estradiol and norgestimate. The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation. Norgestimate and its active metabolite norelgestromin bind to progesterone receptors in the cervix to thicken cervical mucus, impeding sperm penetration, and alter the endometrium.
One tablet orally once daily for 21 consecutive days, followed by 7 drug-free days. Each tablet contains levonorgestrel 0.1 mg and ethinyl estradiol 0.02 mg.
500 mg orally every 6 hours for 10 days.
None Documented
None Documented
Levonorgestrel: terminal half-life 27.7 ± 7.2 hours; ethinyl estradiol: terminal half-life 15.4 ± 8.4 hours. Steady-state achieved within 7–14 days.
Terminal elimination half-life is approximately 2.5 hours in patients with normal renal function; prolonged to >24 hours in severe renal impairment (CrCl <30 mL/min).
Renal (primarily as metabolites, ~60%), fecal (~40%), with less than 10% excreted unchanged as ethinyl estradiol and levonorgestrel.
Primarily renal excretion of unchanged drug (80-85%); biliary/fecal elimination accounts for 10-15%.
Category C
Category C
Contraceptive (Hormonal)
Contraceptive (Hormonal)